Loading company details...
Beta
Latest Form 4 (Oct 2, 2026): K. Angela Macfarlane (Director): Grant/Award of 55,924 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | K. Angela Macfarlane | Grant/Award | 55,924 | n/a |
| Oct 2, 2026 | Robert J. Spiegel | Grant/Award | 55,924 | n/a |
| Oct 2, 2026 | Una S. Ryan | Grant/Award | 55,924 | n/a |
| Oct 2, 2026 | Laurence Marton | Grant/Award | 55,924 | n/a |
| Sep 15, 2026 | Mark Voll, Chief Financial Officer | Grant/Award | 80,000 | n/a |
| Jun 24, 2026 | Una S. Ryan | Other (see footnotes) | 47,789 | $200.2K |
| May 21, 2026 | Mark Voll, Chief Financial Officer | Purchase | 25,000 | $19.7K |
| Apr 8, 2026 | Shaun Bagai, Chief Executive Officer | Grant/Award | 946,107 | n/a |
| Apr 8, 2026 | Mark Voll, Chief Financial Officer | Grant/Award | 80,000 | n/a |
| Apr 8, 2026 | Leesa Gentry, Chief Clinical Officer | Grant/Award | 128,550 | n/a |